AstraZeneca PLC (AZN) Release: New PLATO Analysis Evaluates the Influence of High-Sensitivity Troponin Biomarker Status in NSTE-ACS Patients Managed With Revascularization or Medical Management  
11/7/2012 10:38:22 AM

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced results from a post-hoc analysis of a sub-group of the PLATO study. This new analysis evaluated outcomes in 9,946 patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) managed with or without in-hospital revascularization in relation to measurements at randomization of high-sensitivity troponin-T (hs-TnT), a biomarker test that may be a more sensitive indicator of ongoing heart muscle damage than previously available troponin tests.